Phase 3 Chronic Rhinosinusitis Trial, Recruiting NCT05157685 Sponsor: Centre Hospitalier Intercommunal Creteil Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 3 Chronic Rhinosinusitis Trial, Recruiting

NCT05157685
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old
  • You have had a sinus condition (chronic rhinosinusitis) lasting more than 12 weeks, affecting both sides of your nose and sinuses, with swelling of the nasal lining and thick, discoloured mucus (confirmed by a camera examination of your nose)
  • A scan of your sinuses shows widespread blockage on both sides, including at least the cheek sinuses (maxillary) and the sinuses between and behind the eyes (ethmoids)
  • Your sinus infection has not improved despite trying at least 2 courses of antibiotics
  • You have signed a consent form agreeing to take part
  • You are covered by a health insurance plan

Who may not be able to join:

  • You are pregnant or breastfeeding
  • Your sinus condition is caused by a known underlying condition, such as an immune deficiency, cystic fibrosis, or HIV
  • Your sinus condition does not involve pus (for example, nasal polyps or allergy-related sinusitis)
  • Your sinus problem affects only one side, or only one specific sinus
  • You have severe liver disease (confirm with trial site)
  • You have severe kidney disease (confirm with trial site)
  • You have severe heart failure, including specific heart and kidney complications (confirm with trial site)
  • You have a documented moderate or significant pre-existing hearing loss in one or both ears
  • You have major difficulties with memory or thinking, or you cannot read French well enough to complete questionnaires
  • You have a rare inherited condition affecting how your body handles certain sugars (galactose intolerance, lactase deficiency, or glucose-galactose malabsorption)
  • You have an allergy to peanuts or soy
  • You are allergic to a group of antibiotics called macrolides (e.g. azithromycin, erythromycin)
  • You are allergic or intolerant to any ingredient in azithromycin or the dummy (placebo) treatment used in this trial
  • You have taken azithromycin in the past 3 months
  • You have a heart rhythm problem, an abnormally long electrical signal in your heart (long QT interval), or a slow heart rate (below 60 beats per minute)
  • You have low levels of potassium or magnesium in your blood
  • You have a suspected or confirmed infection with atypical mycobacteria (a specific type of bacterial infection — confirm with trial site)
  • You are taking certain medications that cannot be safely combined with macrolide antibiotics, including some cholesterol medications (atorvastatin, simvastatin), ciclosporin, digoxin, certain heart rhythm drugs, certain antipsychotics, certain antidepressants, certain antibiotics (some fluoroquinolones), ivabradine, colchicine, ergotamine, cisapride, or vitamin K antagonists (confirm with trial site for the full list)
  • You are taking medications that lower potassium levels or slow your heart rate
  • You have severe bile flow problems (severe cholestasis)
  • You are under a legal guardianship arrangement
  • You have a blood cancer and have had a stem cell transplant
  • You have previously had radiotherapy to your face
  • You have a history of cancer in your sinuses or nose
  • You are currently taking part in, or have taken part in, another similar clinical trial within the past month

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0145175000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Centre Hospitalier Intercommunal Creteil
Registry
ClinicalTrials.gov
Start date
21 November 2022
Est. completion
21 November 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Comparison of sinonasal outcome test (SNOT) 22

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov